Compare Cytokinetics Inc (CYTK) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Oscar Health Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Oscar Health Inc is the larger of the two by market cap, and Oscar Health Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Oscar Health Inc for 15 Days on average.
| CYTK | OSCR | |
|---|---|---|
Market Cap | $8.62B | $10.22B |
Volume | 2,594,626 | 4,123,394 |
Sector | Health | Health |
52-Week High | $87.26 | $33.81 |
52-Week Low | $54.76 | $10.85 |
Typical Hold Time | 19 Days | 15 Days |
Enterprise Value | $8.72B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
OSCR trades at $33.1, up 0.58% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $11.7B in 2025 to a projected $15.3B in 2026, turning to a net profit. Analyst consensus is a $34 price target, with 31% buy ratings. Recent news highlights market share gains and raised 2026 guidance following its Investor Day.
The outlook is positive, driven by execution in the ACA market and new growth avenues, but risks include rising medical costs threatening profitability and a high P/E ratio. The stock offers growth potential if margin expansion continues as guided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
